graph Evidence gap map comparisons
avelumab based treatmentnivolumab based treatmentpembrolizumab based treatment
avelumab alone nivolumab alone nivolumab plus SoC pembrolizumab alone pembrolizumab plus SoC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2    
mGC or mGEJC - L1 - HER2 negative 1   
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive 4       
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population 4       
mGC or mGEJC - L2 - PDL1 positive 1   
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative 1   
mGC or mGEJC - M - HER2 neg/PDL1 positive 1   
Comparator:  vs Standard of Care (SoC);   vs placebo plus SoC;   vs placebo;   vs paclitaxel; 
Risk of bias:  low;   some concerns;   high;  NA;